Literature DB >> 1000515

Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.

R T Eagan, R G Hahn, R P Myers.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1000515

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  7 in total

1.  An A,B,C,D of cancer chemotherapy.

Authors:  E Y Chan; R J Cohen
Journal:  West J Med       Date:  1979-06

Review 2.  Update in cancer chemotherapy: genitourinary tract cancer, Part 3: Cancer of the prostate.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-03       Impact factor: 1.798

3.  Phase II trial of menogaril in metastatic adenocarcinoma of the prostate. A Southwest Oncology Group study.

Authors:  S A Taylor; B A Blumenstein; R L Stephens; E D Crawford; B Pistone; J B Hill
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

4.  Treatment of an Nb-Pr-A.I.-3 (autonomous) tumor with combination chemotherapy.

Authors:  J R Drago; T Worgul
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma.

Authors:  T Otto; K Rembrink; M Goepel; M Meyer-Schwickerath; H Rübben
Journal:  Urol Res       Date:  1993

6.  Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer.

Authors:  H Fuse; Y Muraishi; Y Fujishiro; T Katayama
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 7.  Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.

Authors:  Eric Winquist; Tricia Waldron; Scott Berry; D Scott Ernst; Sébastien Hotte; Himu Lukka
Journal:  BMC Cancer       Date:  2006-05-02       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.